Combination of Henagliflozin and Continuous Subcutaneous Insulin Infusion in T2DM
Status:
Not yet recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
The Multi-center, randomized, controlled clinical trial investigate the efficacy and safety
of Henagliflozin combined with continuous subcutaneous insulin infusion in newly diagnosed
type 2 diabetes
Phase:
Phase 4
Details
Lead Sponsor:
First Affiliated Hospital of Guangxi Medical University